Ecor1 Capital, Llc Sells 456,000 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Rating) major shareholder Ecor1 Capital, Llc sold 456,000 shares of Voyager Therapeutics stock in a transaction on Monday, January 9th. The shares were sold at an average price of $7.67, for a total value of $3,497,520.00. Following the transaction, the insider now owns 4,297,907 shares in the company, valued at approximately $32,964,946.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Wednesday, January 11th, Ecor1 Capital, Llc sold 110,000 shares of Voyager Therapeutics stock. The shares were sold at an average price of $8.50, for a total value of $935,000.00.

Voyager Therapeutics Price Performance

Shares of NASDAQ VYGR opened at $9.29 on Friday. The business’s 50-day moving average price is $5.93 and its two-hundred day moving average price is $6.11. Voyager Therapeutics, Inc. has a one year low of $2.60 and a one year high of $10.60. The company has a market capitalization of $358.66 million, a P/E ratio of -20.20 and a beta of 0.93.

Institutional Trading of Voyager Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Armistice Capital LLC lifted its position in shares of Voyager Therapeutics by 32.4% in the third quarter. Armistice Capital LLC now owns 3,396,000 shares of the company’s stock worth $20,104,000 after buying an additional 832,000 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Voyager Therapeutics by 1.9% in the third quarter. Price T Rowe Associates Inc. MD now owns 843,711 shares of the company’s stock worth $4,996,000 after buying an additional 15,761 shares during the last quarter. Millennium Management LLC lifted its position in shares of Voyager Therapeutics by 291.0% in the second quarter. Millennium Management LLC now owns 828,796 shares of the company’s stock worth $4,898,000 after buying an additional 616,814 shares during the last quarter. BlackRock Inc. lifted its position in shares of Voyager Therapeutics by 4.7% during the 3rd quarter. BlackRock Inc. now owns 590,504 shares of the company’s stock worth $3,496,000 after purchasing an additional 26,289 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in shares of Voyager Therapeutics during the 3rd quarter worth about $1,713,000. Institutional investors and hedge funds own 59.58% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, November 14th.

About Voyager Therapeutics

(Get Rating)

Voyager Therapeutics, Inc, a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy.